Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Osteoarthritis Knee
Interventions: Gel-One, PBS; Device
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 38 more

Conditions: Pain
Interventions: J tip, Pain Ease Spray, 1% buffered lidocaine, placebo cooling spray (normal saline spray), Sucrose; Device · Other · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 6 Months to 6 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cholera
Interventions: PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 3,146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 19
States / cities: Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 15 more

Conditions: Moderate or Severe Submental Fullness
Interventions: Deoxycholic acid injection, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: HIV Infections
Interventions: Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant; Biological
Lead sponsor: Madhu Chhanda Choudhary; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Plasmodium Falciparum Malaria
Interventions: Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Campylobacter Infection
Interventions: ALFQ, CJCV2; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Post-traumatic Stress Disorder
Interventions: Stellate Ganglion Block, Sham Stellate Ganglion Block; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Long Beach, California • Tampa, Florida • Minneapolis, Minnesota + 3 more

Conditions: Intraocular Lens Replacement
Interventions: OMS302, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more

Conditions: Pain
Interventions: Buffered Lidocaine J-tip; Drug
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: Up to 90 Days
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Keratoconus, Keratoconus, Unstable
Interventions: Riboflavin 5'-Phosphate; Drug
Lead sponsor: Comprehensive EyeCare of Central Ohio; Other
Eligibility: 14 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Westerville, Ohio

Conditions: Dry Eye
Interventions: Brimonidine Tartrate, Placebos; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 16
States / cities: Newport Beach, California • Rancho Cordova, California • Pompano Beach, Florida + 11 more

Conditions: Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions: iSCIB1+, Nivolumab & Ipilimumab, Placebo; Biological · Drug · Other
Lead sponsor: Scancell Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pain, Local Anesthesia for Peripheral Intravenous Catheterization
Interventions: Lidocaine, Buffered Lidocaine, Bacteriostatic Normal Saline; Drug
Lead sponsor: Allina Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Low-Grade B-cell Lymphoma
Interventions: rhuFlt3L/CDX-301, Poly-ICLC; Drug
Lead sponsor: Joshua Brody; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Septic Shock
Interventions: FE 202158 1.25, FE 202158 2.5, FE 202158 3.75, Placebo; Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Newark, Delaware • Springfield, Massachusetts • Duluth, Minnesota + 3 more

Conditions: Fanconi Anemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: biologic sample preservation procedure, biopsy; Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Shigellosis
Interventions: Flexyn2a, Placebo, Flexyn2a plus adjuvant; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Anthrax
Interventions: AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL); Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more

Conditions: Healthy Volunteers
Interventions: TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Galveston, Texas • Seattle, Washington

Conditions: Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions: Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System; Drug · Device
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Familial Amyotrophic Lateral Sclerosis
Interventions: ISIS 333611; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Charlestown, Massachusetts • St Louis, Missouri + 1 more

Conditions: Meningococcal Infections
Interventions: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals); Biological
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Oakland, California • Worcester, Massachusetts

Conditions: Scoliosis Idiopathic, Scoliosis;Congenital
Interventions: Normosol-R, buffered 2% hypertonic saline; Drug
Lead sponsor: Joseph D. Tobias; Other
Eligibility: 10 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Gel-One Treatment in Knee Osteoarthritis

The Use of Jet Injection Lidocaine for Blood Draws in Young Children

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

Safety and Immunogenicity of CJCV2 With and Without ALFQ

Stellate Ganglion Block for PTSD

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Needle-Free Jet Injection of Lidocaine During Lumbar Puncture

Epi-On Corneal Crosslinking for Keratoconus

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

Local Anesthetics for Pain Reduction Prior to IV Line Placement

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Tissue Sample Collection From Patients With Fanconi Anemia

Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a

Anthrax AV7909 Boost Evaluation Study

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Hypertonic Saline in Posterior Spinal Fusion